公开(公告)号：US20250064871A1

公开(公告)日：2025-02-27

申请号：US18728163

申请日：2023-01-18

Applicant: The Regents of The University of California

Inventor： Anahid Jewett

IPC: A61K35/745 ,  A61K31/198 ,  A61K31/337 ,  A61K31/4985 ,  A61K31/519 ,  A61K33/243 ,  A61K35/00 ,  A61K35/744 ,  A61K35/747 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00

Abstract: The present application relates to probiotic compositions comprising two or more bacterial strains selected from: Bifidobacterium longum, Bifidobacterium breve, Bifidobacterium infantis, Streptococcus thermophiles, Lactobacillus acidophilus, Lactobacillus plantarum, and Lactobacillus paracasei.

公开(公告)号：US20250025518A1

公开(公告)日：2025-01-23

申请号：US18714852

申请日：2022-11-22

Applicant: Inner Mongolia Yili Industrial Group Co., Ltd. ,  INNER MONGOLIA DAIRY TECH RES INSTITUTE CO LTD

Inventor： Wei-Lian Hung ,  Yujie Shi ,  Wei-Hsien Liu ,  Haotian Feng ,  Biao Liu ,  Wei Li ,  Qingshan Chen ,  Mingqiao Zhou

IPC: A61K35/745 ,  A61K31/7016 ,  A61K31/702 ,  A61P19/00

Abstract: Disclosed is the use of Bifidobacterium lactis BL-99 in the protection of cartilage. Provided in the present invention is the use of Bifidobacterium lactis in the preparation of a composition for protecting cartilage, wherein the Bifidobacterium lactis is Bifidobacterium lactis with the deposit number of CGMCC No. 15650. The Bifidobacterium lactis can promote the development of cartilage, increase cartilage density, protect cartilage from damage, promote cartilage repair and/or ameliorate cartilage damage, and is beneficial to cartilage health.

公开(公告)号：US20250009816A1

公开(公告)日：2025-01-09

申请号：US18219649

申请日：2023-07-08

Applicant: GutMind Corp

Inventor： Akbar Farzin Javan

IPC: A61K35/745 ,  A61K35/742 ,  A61K35/747

Abstract: An engineered probiotics platform for in-situ conversion of simple sugars, which are consumed at an unhealthy level in the Western diet, to key functional ingredients such as omega-3 fatty acids, which are critically lacking in the Western diet.

公开(公告)号：US20250009811A1

公开(公告)日：2025-01-09

申请号：US18748761

申请日：2024-06-20

Applicant: Vedanta Biosciences, Inc.

Inventor： Silvia Caballero ,  Cintia Felix

IPC: A61K35/74 ,  A61K9/00 ,  A61K35/742 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747 ,  A61P31/04

Abstract: Provided herein are compositions and methods for the suppression of multi-drug resistant organisms. Provided herein are compositions and methods for treating diseases or disorders associated with bacterial colonization or treating diseases or disorders associated with an immune response induced by bacteria. Also provided herein are compositions and methods for suppressing colonization of the intestine of subject with oral microbiome bacteria.

公开(公告)号：US12156859B2

公开(公告)日：2024-12-03

申请号：US18082723

申请日：2022-12-16

Applicant: Tainnovation Inc

Inventor： Jhen-Wei Ruan ,  Chih-Cheng Tai ,  Cheng-Yuan Kao

IPC: A61K31/198 ,  A61K35/741 ,  A61K35/742 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747 ,  A61K47/26 ,  A61P3/04

Abstract: The present disclosure relates to utilizing the N6-methyllysine for reducing fat percentage in an organ or tissue or for treating obesity, obesity-related diseases or cancers. More specifically, the present invention relates to the method using Nε-Methyl-L-lysine or Nε-Methyl-L-lysine producing bacteria or Nε-Methyl-L-lysine/l-lysine mixture or Nε-Methyl-L-lysine/probiotics mixture to treat obesity, obesity-related diseases or cancers.

公开(公告)号：US12115199B2

公开(公告)日：2024-10-15

申请号：US15862201

申请日：2018-01-04

Applicant: NCH Corporation

Inventor： Scott M. Boyette ,  Judith G. Pruitt ,  John Knope ,  Adrian Denvir ,  Charles Greenwald ,  Alex Erdman

IPC: A61K35/745 ,  A01G22/00 ,  A01K5/00 ,  A01K7/00 ,  A01K7/02 ,  A23K10/18 ,  A61D7/00 ,  A61K35/741 ,  A61K35/742 ,  A61K35/744 ,  A61K35/00

CPC classification number: A61K35/745 ,  A01G22/00 ,  A01K5/00 ,  A01K7/00 ,  A01K7/02 ,  A23K10/18 ,  A61D7/00 ,  A61K35/741 ,  A61K35/742 ,  A61K35/744 ,  A61K2035/115

Abstract: Probiotic compositions that comprise one or more bacteria species in spore form, a thickener to form a stabilized suspension and to preferably act as a prebiotic, one or more acids or salts of acids, and optionally a water activity reducer. A system for delivering probiotic compositions by gravity feed or non-contact pump to a point of consumption by a plant or animal, preferably in conjunction with acidified drinking water, comprising a collapsible container with attachable tubing that prevent contamination of the probiotic composition within the container. Delivery may be actuated in response to a timer, motion detector, fluid level sensor, RFID tag, or other mechanism to periodically or continuously dispense a dosage of probiotic composition directly to the soil surrounding a plant or to the water or feed for an animal. A method for increasing beneficial bacteria in an animal's GIT comprises adding probiotics to acidified drinking water.

公开(公告)号：US20240316128A1

公开(公告)日：2024-09-26

申请号：US18427867

申请日：2024-01-31

Applicant: Unique Biotech Limited

Inventor： Manoj Pandurang Dandekar ,  Shubham Gopal Ghuge ,  Ziaur Rahman ,  Ratna Sudha Madempudi

IPC: A61K35/747 ,  A61K31/198 ,  A61K35/742 ,  A61K35/745 ,  A61P25/00

CPC classification number: A61K35/747 ,  A61K31/198 ,  A61K35/742 ,  A61K35/745 ,  A61P25/00

Abstract: The current invention discloses the use of a multi-strain probiotic formulation comprising one or more novel Lactobacilli, Bifidobacterium and Bacillus strains for the alleviation, prevention and treatment of obsessive-compulsive disorder and/or obsessive-compulsive disorder like symptoms. The multi-strain probiotic formulation disclosed herein for use as treatment for obsessive-compulsive disorder symptoms comprises Bacillus coagulans Unique IS-2, Lactobacillus plantarum UBLP-40, Lactobacillus rhamnosus UBLR-58, Bifidobacterium lactis UBBLa-70, Bifidobacterium breve UBBr-01, and Bifidobacterium infantis UBBI-01.

公开(公告)号：US20240307468A1

公开(公告)日：2024-09-19

申请号：US18419725

申请日：2024-01-23

Applicant: LACTOMASON CO., LTD. ,  BINGGRAE CO., LTD.

Inventor： Minn SOHN ,  Je Seong PARK ,  Ye Ji YOU ,  Young Sup SHIN ,  Sung Hwan KIM ,  Chul Hong KIM

IPC: A61K35/747 ,  A23C9/123 ,  A61K35/744 ,  A61K35/745 ,  C12N1/20 ,  C12R1/225

CPC classification number: A61K35/747 ,  A23C9/1234 ,  A61K35/744 ,  A61K35/745 ,  C12N1/205 ,  A23V2400/113 ,  A23V2400/123 ,  A23V2400/175 ,  A23V2400/249 ,  A23V2400/531 ,  C12R2001/225

Abstract: The present disclosure relates to an immune-enhancing composition comprising Lactobacillus rhamnosus LM1019 and starter strains. An immune-enhancing composition comprising Lactobacillus rhamnosus LM1019 and starter strains according to the present disclosure has an excellent immune-enhancing effect by increasing the amount of nitric oxide (NO) produced and improving the TNF-α secretion ability. Also, since the immune-enhancing composition contains the starter strain, it can be used to produce fermented milk. Under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, the Lactobacillus rhamnosus LM1019 strain was deposited with the international depositary authority: the Korean Culture Center of Microorganisms (KCCM) on Aug. 11, 2017, under the Accession Number: KCCM12308P.

公开(公告)号：US20240293483A1

公开(公告)日：2024-09-05

申请号：US18578507

申请日：2022-07-13

Applicant: AB-BIOTICS, S.A.

Inventor： Marta PÉREZ GARCIA ,  Jordi ESPADALER MAZO

IPC: A61K35/745 ,  A61K31/702 ,  A61P1/00 ,  C12N1/20 ,  C12P9/00

CPC classification number: A61K35/745 ,  A61K31/702 ,  A61P1/00 ,  C12N1/20 ,  C12P9/00

Abstract: A probiotic composition comprising Bifidobacterium longum subsp. longum CECT 7894 is provided. The probiotic composition is useful in treating, preventing, or ameliorating an intestinal barrier dysfunction (e.g., increased intestinal permeability) or associated condition, or symptoms, complications and/or sequela thereof in a subject in need thereof, by producing polyphosphate. A combination of the probiotic composition with at at least one human milk oligosaccharide is also provided.

公开(公告)号：US20240293473A1

公开(公告)日：2024-09-05

申请号：US18424075

申请日：2024-01-26

Applicant: Viktor Veniaminovich TETS ,  Georgy Viktorovich TETS

Inventor： Viktor Veniaminovich TETS ,  Georgy Viktorovich TETS

IPC: A61K35/74 ,  A61K31/65 ,  A61K31/7004 ,  A61K33/06 ,  A61K35/745 ,  A61K35/747 ,  A61K35/76 ,  A61K38/08 ,  A61K38/17 ,  A61K38/46 ,  A61K39/00 ,  A61K39/108 ,  A61P3/10 ,  C07K16/12 ,  C12N15/113 ,  C12Q1/6883

CPC classification number: A61K35/74 ,  A61K31/65 ,  A61K31/7004 ,  A61K33/06 ,  A61K35/745 ,  A61K35/747 ,  A61K35/76 ,  A61K38/08 ,  A61K38/1709 ,  A61K38/465 ,  A61K39/0258 ,  A61P3/10 ,  C07K16/1232 ,  C12N15/113 ,  C12Q1/6883 ,  A61K2039/505 ,  C12N2310/14 ,  C12Q2600/118 ,  C12Q2600/156

Abstract: Methods for preventing, treating or diagnosing Type 1 Diabetes (T1D) are described. Amyloid-producing bacteria within microbiota are inactivated. Amyloid-producing bacteria are inactivated in microbiota, gastrointestinal tract, bodily fluids or tissues. Type-1 Diabetes associated microbial product production or release by microbiota is prevented. Also described is inactivation of bacteria-derived T1DAMP present in microbiota, bodily fluids or tissues of a mammal. Release of bacteria-derived T1DAMP from biofilm or bacteria to gastrointestinal tract is inhibited. Entry of bacteria-derived T1DAMP to microbiota, gastrointestinal tract, bodily fluids or tissues of a mammal is inhibited.